Brief: Tiziana Life Sciences Announces Additional Clinical Improvements
03/01/2023 13:19
Jan 3 (Reuters) - Tiziana Life Sciences Ltd TLSA.O :
* TIZIANA LIFE SCIENCES ANNOUNCES ADDITIONAL CLINICAL
IMPROVEMENTS
IN THE SECOND PATIENT WITH NON-ACTIVE SECONDARY PROGRESSIVE
MULTIPLE SCLEROSIS (SPMS) AFTER ELEVEN MONTHS OF DOSING WITH
INTRANASAL FORALUMAB
Source text for Eikon: ID:nGNXbKCtyt
Further company coverage: TLSA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Tiziana Life Sciences
See all newsBrief: Tiziana Announces New Positive Clinical Data For Intranasal Foralumab In Non-Active Secondary Progressive Multiple Sclerosis
U.S. STOCKS ON THE MOVE -Viatris, Clear Secure, Bicara
U.S. STOCKS ON THE MOVE-Sharps Technology, Whirlpool, Applovin
U.S. STOCKS ON THE MOVE-Oracle, Vanda, Keysight
Tiziana Life Sciences rises as nasal MS drug shows promise in early study